Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Prothena Corp. plc
DescriptionHumanized mAb targeting amyloid
Molecular Target Amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAmyloidosis
Indication DetailsTreat amyloid A (AA) amyloidosis; Treat amyloid light-chain (AL) amyloidosis
Regulatory Designation U.S. - Fast Track (Treat amyloid A (AA) amyloidosis)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today